NASDAQ:IDXX

IDEXX Laboratories Stock Forecast, Price & News

$528.46
+14.30 (+2.78 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$518.47
Now: $528.46
$530.27
50-Day Range
$472.11
MA: $497.22
$538.17
52-Week Range
$256.42
Now: $528.46
$573.99
Volume438,401 shs
Average Volume465,255 shs
Market Capitalization$45.25 billion
P/E Ratio92.07
Dividend YieldN/A
Beta0.88
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services, which are used to manage the health status of livestock and poultry, to improve producer, and to ensure the quality and safety of milk and food. The Other operating segment combines and presents products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.
IDEXX Laboratories logo

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IDXX
CUSIP45168D10
Phone(207) 556-0300
Employees9,000
Year Founded1983

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.41 billion
Cash Flow$6.39 per share
Book Value$2.07 per share

Profitability

Net Income$427.72 million

Miscellaneous

Market Cap$45.25 billion
Next Earnings Date5/4/2021 (Confirmed)
OptionableOptionable

Headlines

1 Growth Driver Idexx Shareholders Should be Watching
April 14, 2021 |  finance.yahoo.com
Is IDEXX Lab. (IDXX) A Smart Long-Term Buy?
March 23, 2021 |  finance.yahoo.com
Is IDEXX Laboratories (IDXX) Stock A Buy or Sell?
March 21, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.46 out of 5 stars

Medical Sector

571st out of 2,021 stocks

Diagnostic Substances Industry

9th out of 32 stocks

Analyst Opinion: 1.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$528.46
+14.30 (+2.78 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

Is IDEXX Laboratories a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IDEXX Laboratories stock.
View analyst ratings for IDEXX Laboratories
or view top-rated stocks.

What stocks does MarketBeat like better than IDEXX Laboratories?

Wall Street analysts have given IDEXX Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IDEXX Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for IDEXX Laboratories
.

How can I listen to IDEXX Laboratories' earnings call?

IDEXX Laboratories will be holding an earnings conference call on Tuesday, May 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Tuesday, February, 2nd. The company reported $2.01 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.39 by $0.62. The company earned $720.90 million during the quarter, compared to analyst estimates of $680.03 million. IDEXX Laboratories had a trailing twelve-month return on equity of 198.91% and a net margin of 19.20%. The business's revenue for the quarter was up 19.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.04 EPS.
View IDEXX Laboratories' earnings history
.

How has IDEXX Laboratories' stock been impacted by Coronavirus?

IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IDXX stock has increased by 115.2% and is now trading at $528.46.
View which stocks have been most impacted by COVID-19
.

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories announced that its Board of Directors has initiated a stock repurchase program on Wednesday, February 12th 2020, which allows the company to repurchase 5,000,000 shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's board believes its stock is undervalued.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY21 earnings guidance on Tuesday, February, 2nd. The company provided EPS guidance of $7.39-7.71 for the period, compared to the Thomson Reuters consensus estimate of $6.79. The company issued revenue guidance of $3.065-3.120 billion, compared to the consensus revenue estimate of $2.95 billion.

What price target have analysts set for IDXX?

5 brokers have issued twelve-month price objectives for IDEXX Laboratories' stock. Their forecasts range from $375.00 to $600.00. On average, they expect IDEXX Laboratories' stock price to reach $471.40 in the next year. This suggests that the stock has a possible downside of 10.8%.
View analysts' price targets for IDEXX Laboratories
or view top-rated stocks among Wall Street analysts.

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the following people:
  • Jonathan J. Mazelsky, President, Chief Executive Officer & Director
  • John Hart, Senior Vice President-Worldwide Operations
  • Brian Patrick McKeon, Chief Financial Officer, Treasurer & Executive VP
  • Jeffrey Thomas, Chief Technology Officer & Senior VP
  • Ken Grady, Chief Information Officer & Senior VP

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories CEO Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among IDEXX Laboratories' employees.

Who are some of IDEXX Laboratories' key competitors?

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Square (SQ), The Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by many different institutional and retail investors. Top institutional investors include Welch & Forbes LLC (0.21%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.17%), Royal London Asset Management Ltd. (0.12%), Chicago Capital LLC (0.09%), Capital Investment Services of America Inc. (0.05%) and Spence Asset Management (0.04%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jay Mazelsky, Jonathan Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends for IDEXX Laboratories
.

Which major investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, EFG Asset Management Americas Corp., Spence Asset Management, Baldwin Brothers Inc. MA, Woodstock Corp, Retirement Systems of Alabama, Pensionfund Sabic, and Welch & Forbes LLC. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson, and Sophie V Vandebroek.
View insider buying and selling activity for IDEXX Laboratories
or view top insider-selling stocks.

Which major investors are buying IDEXX Laboratories stock?

IDXX stock was purchased by a variety of institutional investors in the last quarter, including Royal London Asset Management Ltd., DnB Asset Management AS, Teamwork Financial Advisors LLC, Scout Investments Inc., Everence Capital Management Inc., Leith Wheeler Investment Counsel Ltd., Paragon Advisors LLC, and Loring Wolcott & Coolidge Fiduciary Advisors LLP MA.
View insider buying and selling activity for IDEXX Laboratories
or or view top insider-buying stocks.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $528.46.

How much money does IDEXX Laboratories make?

IDEXX Laboratories has a market capitalization of $45.25 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

IDEXX Laboratories employs 9,000 workers across the globe.

When was IDEXX Laboratories founded?

IDEXX Laboratories was founded in 1983.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is www.idexx.com.

Where are IDEXX Laboratories' headquarters?

IDEXX Laboratories is headquartered at ONE IDEXX DRIVE, WESTBROOK ME, 04092.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at (207) 556-0300 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.